Shattuck Labs Announces Participation in Upcoming September Investor Conferences
Shattuck Labs, a clinical-stage biotech company focused on developing monoclonal and bispecific DR3 blocking antibodies for inflammatory and immune diseases, announced that management will participate in the Wells Fargo 21st Annual Healthcare Conference and the Cantor Global Healthcare Conference in September 2026. The presentations will include fi…